Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

Encouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial

MELBOURNE, Australia, Feb. 26, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has completed initial analysis of wound surface area in the first 16 patients in its Phase 1 clinical...

2024-02-26 14:37 1209

Pierre Fabre Laboratories, committed to combating rare pediatric diseases via innovative therapies

70% of rare genetic diseases start in childhood[1,2] CASTRES, France, Feb. 23, 2024 /PRNewswire/ -- Rare Disease Day® will be held onFebruary 29, an opportunity for Pierre Fabre Laboratories to reiterate our desire to provide innovative prescription drugs to children, as young patients require a...

2024-02-23 18:23 1371

CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy

Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) inEurope Positive CHMP opinion is based on pivotal phase-III PROTECT study results European Commission decision is...

2024-02-23 15:00 1443

CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy

Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline

MELBOURNE, Australia, Feb. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its results for the financial year ended31 December 2023. All figures are in AUD$ unless otherwise stated.[1] 2023 highlights * Total Group revenue of $502.5M, an...

2024-02-22 17:31 2070

Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

--VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU-- SHANGHAI, Feb. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s partner Pfizer Inc. (NYSE: PFE) announced that the ...

2024-02-22 08:59 1555

Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA

NANJING, China, Feb. 21, 2024 /PRNewswire/ -- On February 19, 2024, the Journal of American Medical Association•Neurology (JAMA NEUROLOGY, IF: 29.0) published online the key findings of a phase III clinical study (NCT04950920) (the "TASTE-SL Study") investigating Sanbexin® (a combination of edara...

2024-02-21 12:26 1870

Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA

Everest Medicines' Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine

--Cefepime-taniborbactam was superior to meropenem for the composite efficacy endpoint with composite efficacy sustained at late follow-up visit-- SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK)'s licensing partner, Venatorx Pharmaceuticals announced that The New England ...

2024-02-21 09:00 2846

Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA

ROCKVILLIE, MD. and SUZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major di...

2024-02-20 08:22 2556

HKUST Neuroscientists Develop Highly Accurate Universal Diagnostic Blood Test for Alzheimer's Disease and Mild Cognitive Impairment

At a glance: * Remarkably high accuracy rate – over 96% for AD and 87% for MCI; * Applicable across diverse ethnic populations, including Chinese and European; * Enables early detection of AD and subsequent progression; * Captures multiple AD-associated biological pathways; * A game-chan...

2024-02-19 20:18 1644

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis

SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a biotechnology company dedicated to developing and commercializing transformative pharmaceutical, and surgical products that address critical unmet medical needs in ophthalmology, today announced that the Singapore Health ...

2024-02-19 09:00 3072

Everest Medicines Announces Termination of Collaboration Agreements with Providence

-Everest will continue to develop self-discovered products utilizing the mRNA platform- SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative...

2024-02-19 08:20 1571

Pierre Fabre Laboratories and the EspeRare Foundation to be honored with the EURORDIS Company Award for Patient Engagement 2024, in their approach to co-developing a treatment for XLHED.

CASTRES, France and GENEVA, Feb. 15, 2024 /PRNewswire/ -- On February 20, International Ectodermal Dysplasias Awareness Day, Pierre Fabre Laboratories and the EspeRare Foundation will receive the EURORDIS Company Award for Patient Engagement 2024, at the EURORDIS Black Pearl Award Ceremony to be ...

2024-02-15 17:05 1750

Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and royalty payments to VBI, subject to achievement of certain activities Transferring manufacturing technologies of BRII-179 and PreHevbrio/PreHevbri to additional manufacturing sites and expanding footp...

2024-02-14 08:07 3604

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

VANCOUVER, BC, Feb. 13, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has executed the definitive Asset Purchase Agreement datedFebruary 11th, 2024 to acquire the entire portfolio of discovery, preclinical and cli...

2024-02-13 03:26 3750

YS Biopharma Announces US$40 Million Private Placement Financing

GAITHERSBURG, Md., Feb. 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma") along with its subsidiaries ("YS Group" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and th...

2024-02-09 19:30 6093

DKSH Hong Kong Business Unit Healthcare Solidifies Long-Term Partnership with Church & Dwight

DKSH Hong Kong Business Unit Healthcare renews its partnership with Church & Dwight. DKSH continues to provide full agency services with the aim to expand the reach of Church & Dwight's Anusol product range inHong Kong. This collaboration demonstrates DKSH's unwavering commitment to "Healthcare f...

2024-02-08 19:38 2235

DKSH Hong Kong Business Unit Healthcare Solidifies Long-Term Partnership with Church & Dwight

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform

MELBOURNE, Australia , Feb. 8, 2024 /PRNewswire/ --.Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United...

2024-02-08 06:11 1924

Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China

ROCKVILLE, Md. and SUZHOU, China, Feb. 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...

2024-02-07 16:35 4092

The Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications

SUZHOU, China, Feb. 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase Ⅱclinical research results of anti- PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel as first-line treatment in advanced triple-negative breast cancer (TNBC) were ...

2024-02-07 09:50 1683

The Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications

SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field

TOKYO, Feb. 7, 2024 /PRNewswire/ -- SMC Laboratories, Inc. ("SMC Laboratories"), a non-clinical contract research organization (CRO) that provides consulting and contract services for pharmacology studies utilizing technology and know-how related toMetabolic dysfunction associated steatohepatiti...

2024-02-07 02:00 1457

1 ... 5 6 789 10 11 ... 181